Mastocytosis

Middleton's Allergy: Principles and Practice: Eighth Edition

Volumn 2-2, Issue , 2014, Pages 1224-1236

  Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898812719     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-08593-9.00077-2     Document Type: Chapter

References (51)

1. Horny H-P, Metcalfe DD, Bennett JM, et al. Mastocytosis. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, 54-63. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
2. Ehrlich P Beitrage zur theorie und praxis der histologischen färbung 1878, University of Leipzig.
3. Unna PG Die spezifische färbung der mastzellenkörnung. Monatsh Prakt Dermatol 1894, 19:367.
4. Webb RL Peritoneal reactions in the white rat, with especial reference to the mast cells. Am J Anat 1931, 49:283-334.
5. Jorpes JE The site of formation of heparin. Heparin: its chemistry, physiology, and application in medicine 1939, 30. Humphrey Milford (Oxford University Press), London.
6. Riley JF Histamine in tissue mast cells. Science 1953, 118(3064):332.
7. Nettleship E, Tay W Rare forms of urticaria. BMJ 1869, 2:323-330.
8. Sangster A An anomalous mottled rash, accompanied by pruritus, factitious urticaria and pigmentation, "urticaria pigmentosa?". Trans Clin Soc Lond 1878, 11:161-163.
9. Ellis JM Urticaria pigmentosa: a report of a case with autopsy. AMA Arch Pathol 1949, 48:426-435.
10. Robyn J, Metcalfe DD Systemic mastocytosis. Adv Immunol 2006, 89:169-243.
11. Kirshenbaum AS, Goff JP, Semere T, et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999, 94:2333-2342.
12. Kirshenbaum AS, Goff JP, Kessler SW, et al. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992, 148:772-777.
13. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003, 31:686-692.
14. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995, 92:10560-10564.
15. Wilson TM, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96:459-463.
16. Lasho T, Tefferi A, Pardanani A Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia 2010, 24:1378-1380.
17. Maric I, Robyn J, Metcalfe DD, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007, 120:680-687.
18. Lahortiga I, Akin C, Cools J, et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008, 93:49-56.
19. Garriga MM, Friedman MM, Metcalfe DD A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol 1988, 82:425-432.
20. Soter NA Mastocytosis and the skin. Hematol Oncol Clin North Am 2000, 14:537-555.
21. Parwaresch MR, Horny HP, Lennert K Tissue mast cells in health and disease. Pathol Res Pract 1985, 179:439-461.
22. Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis: a prospective study. Gastroenterology 1988, 95:657-667.
23. Ammann RW, Vetter D, Deyhle P, et al. Gastrointestinal involvement in systemic mastocytosis. Gut 1976, 17:107-112.
24. Bredfeldt JE, O'Laughlin JC, Durham JB, Blessing LD Malabsorption and gastric hyperacidity in systemic mastocytosis: results of cimetidine therapy. Am J Gastroenterol 1980, 74:133-137.
25. Broitman SA, McCray RS, May JC, et al. Mastocytosis and intestinal malabsorption. Am J Med 1970, 48:382-389.
26. Chen CC, Andrich MP, Mican JM, Metcalfe DD A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med 1994, 35:1471-1475.
27. Mican JM, Di Bisceglie AM, Fong TL, et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995, 22:1163-1170.
28. Rogers MP, Bloomingdale K, Murawski BJ, et al. Mixed organic brain syndrome as a manifestation of systemic mastocytosis. Psychosom Med 1986, 48:437-447.
29. McFarlin KE, Kruesi MJ, Metcalfe DD A preliminary assessment of behavioral problems in children with mastocytosis. Int J Psychiatry Med 1991, 21:281-289.
30. Friedman BS, Steinberg SC, Meggs WJ, et al. Analysis of plasma histamine levels in patients with mast cell disorders. Am J Med 1989, 87:649-654.
31. Keyzer JJ, de Monchy JG, van Doormaal JJ, van Voorst Vader PC Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983, 309:1603-1605.
32. 2 in patients with systemic mastocytosis. N Engl J Med 1980, 303:1400-1404.
33. Akin C, Schwartz LB, Kitoh T, et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 2000, 96:1267-1273.
34. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
35. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007, 110:2331-2333.
36. Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001, 357(9253):361-362.
37. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009, 123:680-686.
38. Akin C, Valent P, Metcalfe DD Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010, 126:1099-1104.
39. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2011, 157:215-225.
40. Metcalfe DD Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy Asthma Proc 2000, 21:21-24.
41. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG Systemic mast cell disease: analysis of 58 cases and literature review. Medicine (Baltimore) 1988, 67:345-368.
42. Lawrence JB, Friedman BS, Travis WD, et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991, 91:612-624.
43. Travis WD, Li CY, Hoagland HC, Travis LB, Banks PM Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986, 61:957-966.
44. Frieri M, Alling DW, Metcalfe DD Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis: results of a double-blind clinical trial. Am J Med 1985, 78:9-14.
45. Worobec AS Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000, 14:659-687.
46. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009, 84:790-794.
47. Pardanani A Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87:401-411.
48. Pardanani A, Tefferi A A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol 2010, 84:371-378.
49. Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006, 37:353-358.
50. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113:5727-5736.
51. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114:3769-3772.